eXoZymes (NASDAQ:EXOZ) Trading Down 1.1% – Here’s Why

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price was down 1.1% on Monday . The company traded as low as $4.60 and last traded at $4.60. Approximately 12,408 shares were traded during mid-day trading, an increase of 30% from the average daily volume of 9,573 shares. The stock had previously closed at $4.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, eXoZymes has an average rating of “Sell”.

eXoZymes Stock Performance

The company has a market cap of $50.10 million, a P/E ratio of -4.77 and a beta of 2.93. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average price is $7.18 and its 200 day moving average price is $8.70.

eXoZymes (NASDAQ:EXOZ) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.28) earnings per share for the quarter.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.